Natera stock enters new phase after Q3 growth and CEO change

Published on 11/07/2026 at 10:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Natera stock enters a new leadership phase after a strong quarterly update. Medicare coverage adds support for Signatera's oncology expansion.

Growth, Coverage And Leadership Change

Natera raised its 2026 revenue outlook after reporting strong third-quarter operating growth.
Medicare coverage broadens the potential use of Signatera in early-stage liver cancer surveillance.
Solomon Moshkevich succeeds Steve Chapman as chief executive while Chapman remains an adviser.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera entered a new phase on Thursday, November 5, 2026, after reporting third-quarter growth, lifting its full-year outlook and naming Solomon Moshkevich as chief executive. The company also highlighted a new Medicare coverage decision for its Signatera cancer-monitoring test.

According to Natera's investor release, third-quarter revenue reached 794.0 million US dollars, up 34.1 percent from the same period a year earlier. The company processed about 1.093 million tests, while oncology tests increased 60.9 percent year over year.

Natera raised its 2026 revenue outlook to 3.005 billion to 3.035 billion US dollars from 2.850 billion to 2.910 billion US dollars. The guidance includes a gross-margin range of 64 percent to 66 percent and positive cash flow expectations. The quarter still produced a net loss of 59.9 million US dollars, or 0.42 US dollars per diluted share.

Leadership Change Tests Execution

Natera said Moshkevich took over immediately after Steve Chapman stepped down. Chapman remains a consultant and board adviser. Moshkevich has led several commercial, clinical and oncology functions since joining Natera in 2011, making continuity a central investor question rather than an abrupt strategic reset.

On Tuesday, November 3, Natera announced that Medicare coverage now includes serial Signatera testing for early-stage hepatocellular carcinoma patients under surveillance after surgery. The decision covers patients with no post-surgical evidence of disease and could support broader adoption in oncology monitoring. Natera cited a 125-patient study in which Signatera recorded 83 percent sensitivity and 100 percent specificity.

The real-time quote of Natera stock showed 280.00 euros on Lang & Schwarz at 10:43 CET on Saturday, November 7, 2026.